Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555840 | 1.00 | KMT2A (0.41) | KMT2ATHRBALDH1A1GAALMNA | |
| SCHEMBL31093340 | 0.78 | KMT2A (0.37) | KMT2AALDH1A1MAPTMEN1HTT | |
| SCHEMBL21194413 | 0.78 | KMT2A (0.37) | KMT2AALDH1A1MAPTMEN1HTT | |
| SCHEMBL2233943 | 0.75 | MEN1 (0.34) | KMT2AALDH1A1GAALMNAMAPT | |
| SCHEMBL2233944 | 0.75 | MEN1 (0.34) | KMT2AALDH1A1GAALMNAMAPT | |
| SCHEMBL21192963 | 0.72 | CYP1A2 (0.36) | ALDH1A1GAALMNATSHRMAPT | |
| SCHEMBL21192966 | 0.72 | CYP1A2 (0.36) | ALDH1A1GAALMNATSHRMAPT | |
| SCHEMBL7981948 | 0.72 | LMNA (0.39) | KMT2ATHRBALDH1A1GAALMNA | |
| SCHEMBL14960518 | 0.71 | KMT2A (0.42) | KMT2ATHRBALDH1A1GAALMNA | |
| SCHEMBL20860745 | 0.71 | LMNA (0.33) | KMT2AALDH1A1LMNATSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718801-B2 | Substituted imidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-7709475-B2 | 5-[2-(cyclohexyloxy)-6-methyl-4-pyrimidinyl]-2-[5-(4-methyl-1-piperazinyl)methyl-2-pyrazinyl]amino-1,3-thiazole; anticarcinogenic agent; G1 phase in cell cycle; great selectivity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-04 | — | — | US | disclosed |
| US-20080081811-A1 | Selective Inhibitors Against Cdk4 and Cdk6 Having Aminothiazole Skeleton | BANYU PHARMACEUTICAL CO., LTD (JP) | 2008-04-03 | — | — | US | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | KMT2A 847/4885THRB 3159/4885ALDH1A1 4349/4885 |
| US-20080081811-A1 | Selective Inhibitors Against Cdk4 and Cdk6 Having Aminothiazole Skeleton | CDK4, CDK6, CDK3 | KMT2A 233/4885THRB 2414/4885ALDH1A1 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.